Jonathan Lord - DexCom Independent Chairman of the Board

DXCM Stock  USD 139.48  0.45  0.32%   

Chairman

Dr. Jonathan T. Lord M.D. is no longer Independent Director of DexCom Inc. effective as of January 1 2017. He has served on our Board since May 2008 and served as our Chairman from May 2010 until December 31 2014 when on January 1 2015 Mr. Gregg became Chairman after resigning as DexComs Chief Executive Officer and served as our Lead Independent Director from January 2015 until November 2015. Recently Dr. Lord served as a professor of pathology at the University of Miamis Miller School of Medicine after serving as the Chief Operating Officer of the Miller School and UHealthUniversity of Miami Health System from March 2012 to January 31 2013. From August 2011 to March 2012 Dr. Lord served as the Chief Innovation Officer at the University of Miami Florida. From April 2009 to January 2010 Dr. Lord served as President and Chief Executive Officer of Navigenics Inc. a privately held healthcare company. From April 2000 to April 2009 Dr. Lord served as Chief Innovation Officer and Senior Vice President at Humana Inc. a health benefits company. From October 1999 to April 2000 Dr. Lord served as President of Health Dialog a health information provider and from April 1997 to October 1999 he served as Chief Operating Officer of the American Hospital Association a national organization representing hospitals health care networks and their patients. Dr. Lord also serves as a director of Biolase Digital Reasoning Par 80 and Velano Vascular. Dr. Lord also serves in an advisory board role for ViaGenetics. From 2012 to 2015 Dr. Lord served in an advisory board role for Third Rock Ventures since 2015.
Age 60
Tenure 9 years
Professional MarksPh.D
Address 6340 Sequence Drive, San Diego, CA, United States, 92121
Phone858 200 0200
Webhttps://www.dexcom.com
Lord received a B.S. degree in chemistry and a M.D. degree from the University of Miami. Through Dr. Lord’s experience in healthcare technology and insurance, he provides the Board with senior leadership and critical guidance on issues relating to technology, market and commercial development.

Jonathan Lord Latest Insider Activity

Tracking and analyzing the buying and selling activities of Jonathan Lord against DexCom stock is an integral part of due diligence when investing in DexCom. Jonathan Lord insider activity provides valuable insight into whether DexCom is net buyers or sellers over its current business cycle. Note, DexCom insiders must abide by specific rules, including filing SEC forms every time they buy or sell DexCom'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.

DexCom Management Efficiency

The company has return on total asset (ROA) of 0.0641 % which means that it generated a profit of $0.0641 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.2578 %, meaning that it created $0.2578 on every $100 dollars invested by stockholders. DexCom's management efficiency ratios could be used to measure how well DexCom manages its routine affairs as well as how well it operates its assets and liabilities. As of the 28th of March 2024, Return On Capital Employed is likely to grow to 0.13. Also, Return On Assets is likely to grow to 0.09. At this time, DexCom's Intangible Assets are very stable compared to the past year. As of the 28th of March 2024, Fixed Asset Turnover is likely to grow to 3.41, while Other Current Assets are likely to drop about 25.1 M.
The company currently holds 2.59 B in liabilities with Debt to Equity (D/E) ratio of 1.17, which is about average as compared to similar companies. DexCom Inc has a current ratio of 3.69, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist DexCom until it has trouble settling it off, either with new capital or with free cash flow. So, DexCom's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like DexCom Inc sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for DexCom to invest in growth at high rates of return. When we think about DexCom's use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 4 records

CHAIRMAN Age

David KingLaboratory
61
Isaiah HarrisCigna Corp
68
Cesar AlvarezMednax Inc
71
Adam SchechterLaboratory
59
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring systems in the United States and internationally. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California. Dexcom operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 6300 people. DexCom Inc (DXCM) is traded on NASDAQ Exchange in USA. It is located in 6340 Sequence Drive, San Diego, CA, United States, 92121 and employs 9,500 people. DexCom is listed under Health Care Equipment & Supplies category by Fama And French industry classification.

Management Performance

DexCom Inc Leadership Team

Elected by the shareholders, the DexCom's board of directors comprises two types of representatives: DexCom inside directors who are chosen from within the company, and outside directors, selected externally and held independent of DexCom. The board's role is to monitor DexCom's management team and ensure that shareholders' interests are well served. DexCom's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, DexCom's outside directors are responsible for providing unbiased perspectives on the board's policies.
Eric Topol, Independent Director
Lanny Roper, CFO, Vice President
Shelly Selvaraj, Senior Officer
Matthew Dolan, Corporate Strategy
Patrick Murphy, Chief Compliance Officer, Vice President General Counsel
Mark Foletta, Independent Director
Jonathan Lord, Independent Chairman of the Board
Jacob Leach, Executive COO
Donald Abbey, Executive Vice President Quality and Information Technology
Jay Skyler, Independent Director
Jake Leach, Senior Vice President of Research and Development
Jorge Valdes, Chief Technical Officer and Executive VP
Paul Flynn, Ex Revenue
Kevin Sayer, CEO and President and Director
Terrance Gregg, Executive Chairman
Michael Brown, Executive Officer
Richard Doubleday, Senior Vice President - Worldwide Sales and Marketing
Jess Roper, CFO and Sr. VP
Sean Christensen, Director Relations
Quentin Blackford, CFO
Kevin Sun, Interim CFO
Nicholas Augustinos, Independent Director
Leverne Marsh, Executive Marketing
Jeffrey Moy, Senior Vice President - Operations
Jereme Sylvain, CFO VP
Heather Ace, Senior Vice President Human Resources
Girish Naganathan, Executive CTO
John Lister, Senior Vice President General Counsel
Richard Collins, Independent Director
Sadie Stern, Executive Officer
Barbara Kahn, Independent Director
Steven Pacelli, Executive VP of Strategy and Corporate Devel.
Andrew Balo, Senior Vice President - Clinical and Regulatory Affairs
Steven Altman, Independent Director

DexCom Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is DexCom a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Pair Trading with DexCom

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if DexCom position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in DexCom will appreciate offsetting losses from the drop in the long position's value.

Moving against DexCom Stock

  0.66DH Definitive Healthcare Financial Report 2nd of May 2024 PairCorr
  0.64MMSI Merit Medical Systems Financial Report 24th of April 2024 PairCorr
  0.51FIGS Figs Inc Financial Report 2nd of May 2024 PairCorr
  0.48XAIR Beyond Air Financial Report 27th of June 2024 PairCorr
  0.47TFX Teleflex Incorporated Financial Report 2nd of May 2024 PairCorr
The ability to find closely correlated positions to DexCom could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace DexCom when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back DexCom - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling DexCom Inc to buy it.
The correlation of DexCom is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as DexCom moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if DexCom Inc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for DexCom can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether DexCom Inc is a strong investment it is important to analyze DexCom's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact DexCom's future performance. For an informed investment choice regarding DexCom Stock, refer to the following important reports:
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in DexCom Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators.
Note that the DexCom Inc information on this page should be used as a complementary analysis to other DexCom's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.

Complementary Tools for DexCom Stock analysis

When running DexCom's price analysis, check to measure DexCom's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy DexCom is operating at the current time. Most of DexCom's value examination focuses on studying past and present price action to predict the probability of DexCom's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move DexCom's price. Additionally, you may evaluate how the addition of DexCom to your portfolios can decrease your overall portfolio volatility.
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Global Correlations
Find global opportunities by holding instruments from different markets
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Is DexCom's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of DexCom. If investors know DexCom will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about DexCom listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
1.81
Earnings Share
1.3
Revenue Per Share
9.384
Quarterly Revenue Growth
0.269
Return On Assets
0.0641
The market value of DexCom Inc is measured differently than its book value, which is the value of DexCom that is recorded on the company's balance sheet. Investors also form their own opinion of DexCom's value that differs from its market value or its book value, called intrinsic value, which is DexCom's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because DexCom's market value can be influenced by many factors that don't directly affect DexCom's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between DexCom's value and its price as these two are different measures arrived at by different means. Investors typically determine if DexCom is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, DexCom's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.